As previously reported, Piper Sandler initiated coverage of Tango Therapeutics (TNGX) with an Overweight rating and $11 price target The firm thinks investors are starting to regain confidence in the synthetic lethality space and see potential for Tango’s TNG462 following the positive competitor readthrough presented at ASCO earlier this year. The firm thinks the size and length of follow-up on the second half clinical update in pancreatic cancer and NSCLC can provide support for the potentially differentiated durability of TNG462 and “begin de-risking potential blockbuster opportunities,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics initiated with an Overweight at Piper Sandler
- Tango Therapeutics Reports Q2 2025 Financial Results
- Tango Therapeutics reports Q2 EPS (35c), consensus (34c)
- Tango Therapeutics management to meet with Cantor Fitzgerald
- Tango Therapeutics announces first patient dosed in Phase 1/2 trial of TNG462